It is important to acknowledge that the majority of T2DM patients fall within the category of those without established ASCVD, suggesting that optimizing DPP-4 inhibitor-based treatments will greatly benefit this significant group of patients. The gene discussed is DPP4; the disease is atherosclerosis.